Tzvi Palash joins Protalix BioTherapeutics
pharmafile | September 9, 2010 | Appointment | Manufacturing and Production, Research and Development | Portalix BioTherapeutics, appointment, manufacturing and production, research and development
Protalix BioTherapeutics has appointed Tzvi Palash to the newly-created position of chief operating officer.
He will be responsible for overseeing the Israeli biotech’s manufacturing activities and implementing the expansion of its facilities.
Protalix’s chief executive Dr David Aviezer said: “Protalix is at an exciting stage in its evolution as it prepares for the anticipated launch of taliglucerase alfa for the treatment of Gaucher disease and advances its drug pipeline through clinical development.
“It is crucial that we continue to maintain the quality and supply of our product candidates as we embark on commercialisation and continue to grow. We are delighted to have Tzvi join us, given his experience in manufacturing and commercial operations.”
Tzvi has over 25 years of expertise of commercial operations in the healthcare industry and prior to joining Protalix he served as general manager at J&J subsidiary ColBar LifeScience.
Before this he was plant manager at drug manufacturing facility C.T.S., QA manager at Teva Pharmaceutical Industries and production manager at Serono’s Interpharm Laboratories subsidiary.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …






